ArticleJournal of parasitic diseases : official organ of the Indian Society for Parasitology2025
Unravelling therapeutic potentials of
Article in Journal of parasitic diseases : official organ of the Indian Society for Parasitology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The high prevalence rate of malaria due to the proliferation of drug-resistant strains of Methods: Standard protocols were employed for the semi-purification and characterization; evaluation of antiplasmodial and hepatoprotective assays; retrieval of target proteins from PDB, ADMET, and docking studies. Column and thin layer chromatography and GC-MS aided the semi-purification and characterization of compounds; PKCSM and ADMET Lab 2 enhanced the evaluation of pharmacokinetic properties; AutoDock Vina and PyRx for docking analysis; and Biovia Discovery Studio and PyMol software for the visualization of interactions. Results: The n-hexane extract (20 g) (with the best antiplasmodial therapeutic index) undergone chromatographic analyses and yielded bulked column fractions (A-H); fraction A (1459 mg) was further semi-purified to column sub-fractions A3 (18 mg), A4 (27 mg), and A9 (14 mg); their GC-MS analyses revealed 5-cyano-3-methyoxymethylene cholestane; morphinan-6,10-diol; phthalic acid; protocatechic acid, etc. In silico studies revealed the above lead compounds with better binding affinities to chloroquine, non-inhibition of mono-oxygenases, ease of excretion, non-carcinogenicity, as well as non-violation of Lipinski's criteria. Moreover, the mice's treatment caused increases in SOD, CAT, GPx, and GSH but decreased in MDA, ALT, AST, and ALP, total and conjugated bilirubin levels, with little pathological changes in the liver's histological section that contrasted the evidence in the negative control group. Conclusion: The lead compounds were responsible for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.